Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOKOMEZA: Sudan Ebolavirus Vaccines
NCT05909358Phase 2Not yet recruiting
- Sponsor
- Makerere University
- Start
- Jul 2023
- Primary completion
- Sep 2027
- Modality
- Recombinant Proteins and Enzymes, DNA Vaccines, Live Vector Vaccines
01
Overview
Phase 2, randomised, double-blind trial of cAd3-EBO S, ChAdOx1 biEBOV and Sudan ebolavirus vaccine in Sudan virus disease (SVD) (4 arms), sponsored by Makerere University. Primary endpoints: Incidence of solicited, unsolicited adverse and serious adverse events at 72 months, Vaccine-specific antibody concentration at 72 months and 2 more. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
cAd3-EBO SChAdOx1 biEBOVSudan ebolavirus vaccine
03
Conditions
Sudan virus disease (SVD)
Beyond the preview
Go deeper on NCT05909358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909358.